Horizon 1 1 17 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES JAIDS Journal of Acquired Immune Deficiency Syndromes 418-427 Hiv drug resistance Hiv-1 non-b subtypes Resistance testing Oligonucleotide ligation assay Minor genotypes Point mutation assay Dried blood spots 2008 fdi:010042699 ENG JAIDS Journal of Acquired Immune Deficiency Syndromes 1525-4135 ISI:000257808100006 4 10.1097/QAI.0b013e31817ed7d7 https://www.documentation.ird.fr/hor/fdi:010042699 https://www.documentation.ird.fr/intranet/publi/2008/08/010042699.pdf 48 Horizon (IRD) Objective: We evaluated the feasibility of the oligonucleotide ligation assay (OLA), a specific, sensitive, and economical ligase-based point mutation assay designed to detect HIV-1 drug-resistance mutations at 12 codons of HIV-1 subtype B pol, for potential use in resource-poor settings. Methods: Specimens from HIV-1-infected individuals collected by 7 international laboratories, including subtypes A, B, C, D, F, G, J, and recombinants AE and AG, were tested by the OLA developed for HIV-1 subtype B. Common polymorphisms that interfered with reactivity of the OLA were identified and modified probes designed and evaluated. Results: 92.5% (2410) of 2604 codons in specimens from 217 individuals were successfully genotyped by the subtype B OLA. A high rate (range 8.3%-31.2%) of indeterminate results (negative OLA reaction for both mutant and wild type) was observed for 5 codons. Modified probes at reverse transcriptase codons 151 and 184 and protease codon 90 increased the rate of valid OLA to 96.1%. Conclusions: The OLA designed for HIV-1 subtype B genotyped most pol codons in non-B subtypes from Asia and Africa but was improved by addition of several modified probes. International laboratories experienced in molecular techniques were able to perform the OLA. 052 ; 050 UR174 Chine / Cameroun / Honduras / Inde / Thaïlande / Afrique du Sud